T2 mapping for the characterization of prostate lesions - Takeaways - MDSpire

T2 mapping for the characterization of prostate lesions

  • By

  • Tobias Hepp

  • Laura Kalmbach

  • Manuel Kolb

  • Petros Martirosian

  • Tom Hilbert

  • Wolfgang M. Thaiss

  • Mike Notohamiprodjo

  • Jens Bedke

  • Konstantin Nikolaou

  • Arnulf Stenzl

  • Stephan Kruck

  • Sascha Kaufmann

  • March 31, 2022

  • 0 min

Share

  • 1

    Prostate cancer is the most common non-cutaneous cancer in men, with a lifetime risk of up to 37%.

  • 2

    Multiparametric MRI, including T2-weighted sequences, is the best imaging modality for detecting prostate cancer.

  • 3

    Differentiating prostate cancer from chronic prostatitis in MRI is challenging due to overlapping imaging characteristics.

  • 4

    T2 mapping provides quantitative T2 values that may help differentiate between prostate cancer and chronic prostatitis.

  • 5

    The study analyzed T2 values in 55 patients, comparing them with histopathological findings from targeted biopsies.

Original Source(s)

T2 mapping for the characterization of prostate lesions

  • by Tobias Hepp, Laura Kalmbach, Manuel Kolb, Petros Martirosian, Tom Hilbert, Wolfgang M. Thaiss, Mike Notohamiprodjo, Jens Bedke, Konstantin Nikolaou, Arnulf Stenzl, Stephan Kruck, Sascha Kaufmann

  • March 31, 2022

Related Content

Residual stone fragments: systematic review of definitions, diagnostic standards

Development of a nomogram predicting metastatic disease and the assessment of NCCN, AUA and EAU guideline recommendations for bone imaging in prostate cancer patients

Confocal laser endomicroscopy for upper tract urothelial carcinoma: validation of the proposed criteria and proposal of a scoring system for real-time tumor grading